BioMarin Pharmaceutical (NASDAQ:BMRN) Issues FY 2026 Earnings Guidance

BioMarin Pharmaceutical (NASDAQ:BMRN) updated its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 2.800-3.100 for the period, compared to the consensus EPS estimate of 3.320. The company issued revenue guidance of $3.8 billion-$3.9 billion, compared to the consensus revenue estimate of $3.9 billion.

Analysts Set New Price Targets

Several equities analysts recently issued reports on BMRN shares. Piper Sandler raised their price target on BioMarin Pharmaceutical from $88.00 to $90.00 and gave the company an “overweight” rating in a report on Tuesday, September 1st. Citigroup boosted their price objective on BioMarin Pharmaceutical from $75.00 to $76.00 and gave the stock a “buy” rating in a report on Thursday, July 16th. JPMorgan Chase & Co. increased their price objective on shares of BioMarin Pharmaceutical from $86.00 to $87.00 and gave the company an “overweight” rating in a report on Tuesday, October 20th. HC Wainwright reiterated a “neutral” rating and set a $60.00 target price on shares of BioMarin Pharmaceutical in a research report on Tuesday. Finally, Royal Bank Of Canada decreased their target price on BioMarin Pharmaceutical from $62.00 to $60.00 and set a “sector perform” rating for the company in a research report on Tuesday. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $87.96.

BioMarin Pharmaceutical Price Performance

BMRN opened at $55.66 on Wednesday. The company has a quick ratio of 1.32, a current ratio of 2.39 and a debt-to-equity ratio of 0.56. BioMarin Pharmaceutical has a 12 month low of $49.26 and a 12 month high of $70.98. The company has a fifty day simple moving average of $60.24 and a 200 day simple moving average of $58.45. The stock has a market cap of $10.77 billion, a P/E ratio of -556.60, a P/E/G ratio of 0.63 and a beta of 0.21.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings data on Monday, November 2nd. The biotechnology company reported $0.23 EPS for the quarter, topping the consensus estimate of ($0.05) by $0.28. The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.02 billion. BioMarin Pharmaceutical had a positive return on equity of 5.59% and a negative net margin of 0.52%. The firm’s revenue was up 32.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.12 EPS. On average, research analysts expect that BioMarin Pharmaceutical will post 2.59 EPS for the current year.

Key BioMarin Pharmaceutical News

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Third-quarter revenue rose 32% year over year to about $1.025 billion, in line with expectations, while earnings of $0.23 per share beat estimates for a loss. Growth was led by metabolic and skeletal-condition products. BioMarin Q3 results
• Positive Sentiment: BioMarin added an investigational Fabry asset to its clinical pipeline and reported a May 30, 2027, FDA action date for VOXZOGO in hypochondroplasia. These developments may bolster longer-term growth prospects. Analyst view of BioMarin’s growth potential
• Neutral Sentiment: Analyst views were mixed: Morgan Stanley maintained an Overweight rating despite reducing its target to $119, while RBC lowered its target to $60 and kept Sector Perform; HC Wainwright reiterated Neutral at $60. Morgan Stanley rating information
• Neutral Sentiment: Call-option trading was unusually active, with volume 228% above its typical level. This signals increased trading interest but does not establish a clear direction for the shares.
• Negative Sentiment: BioMarin cut 2026 guidance to $2.80–$3.10 in earnings per share and $3.8–$3.9 billion in revenue, versus consensus of $3.32 and $3.9 billion, respectively. The company cited order-timing uncertainty and charges tied to two acquired research programs, making the weaker outlook a likely near-term overhang despite the quarterly beat. 2026 guidance update

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare diseases. The company’s research and development efforts center on genetic and metabolic disorders, where patient populations are often small and treatment options are limited.

BioMarin’s marketed products include Voxzogo (vosoritide) for children with achondroplasia and open growth plates, Palynziq (pegvaliase) and Kuvan (sapropterin dihydrochloride) for phenylketonuria, Brineura (cerliponase alfa) for late-infantile neuronal ceroid lipofuscinosis type 2, Vimizim (elosulfase alfa) for Morquio A syndrome, and Naglazyme (galsulfase) for mucopolysaccharidosis VI.